Name: Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (en Inglés)
SKU: 58520670
Price: 179.19 USD
Availability: InStock
Author: Bonate, Peter L. ; Howard, Danny R.
ISBN: 9783319818054

portada Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (en Inglés)

Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Bonate, Peter L. ; Howard, Danny R.

Idioma

Inglés

N° páginas

330

Encuadernación

Tapa Blanda

Dimensiones

23.4x15.6x1.8 cm

Peso

0.49 kg.

ISBN13

9783319818054

Categorías

Oncología
Farmacología
Farmacia/prescripción/dispensación

Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (en Inglés)

Bonate, Peter L. ; Howard, Danny R. (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 17 a 24 días háb.

$ 325.80$ 179.19

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 179.19

Llega entre el 23 Sep y el 06 Oct a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (en Inglés)"

In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely - to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist's point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented.